Cat. No. 5033
Chemical Name: 2-(3-Mercaptopropyl)pentanedioic acid
Biological ActivitySelective glutamate carboxypeptidase II (GCP II) inhibitor (IC50 = 90 nM). Selective for GCP II over NMDA, kainate and AMPA glutamate receptors and MMP-1, -2, -3, -7, -9, ACE and NEP metalloproteases. Antinociceptive in a rat model of neuropathic pain and protects against motor neuron death in familial amyotrophic lateral sclerosis mice. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Vornov et al (2013) Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. J.Pharmacol.Exp.Ther. 346 406. PMID: 23776202.
Ghadge et al (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc.Natl.Acad.Sci.U.S.A. 100 9554. PMID: 12876198.
Majer et al (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J.Med.Chem. 46 1989. PMID: 12723961.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses 2-MPPA from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 2-MPPA, supplier, selective, glutamate, carboxypeptidase, 2, II, GCP2, GCPII, inhibitors, inhibits, neuroprotective, antinociceptive, orally, bioavailable, Tocris Bioscience, Carboxypeptidase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailable
April 1 - 5, 2017
Washington, D.C., USA